Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
JNJ's Cash to Debt is ranked higher than
81% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. JNJ: N/A )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.64 Max: 6.28
Current: N/A
0.46
6.28
Equity to Asset 0.53
JNJ's Equity to Asset is ranked lower than
64% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. JNJ: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.53
0.5
0.67
Interest Coverage 34.74
JNJ's Interest Coverage is ranked higher than
56% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. JNJ: 34.74 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.54 Max: 208.73
Current: 34.74
28.29
208.73
F-Score: 6
Z-Score: 5.67
M-Score: -2.64
WACC vs ROIC
7.29%
28.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.71
JNJ's Operating margin (%) is ranked higher than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. JNJ: 26.71 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.14 Max: 28.2
Current: 26.71
22.36
28.2
Net-margin (%) 20.97
JNJ's Net-margin (%) is ranked higher than
88% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. JNJ: 20.97 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 20.97
14.87
21.99
ROE (%) 20.97
JNJ's ROE (%) is ranked higher than
85% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. JNJ: 20.97 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 20.97
17.02
30.17
ROA (%) 11.20
JNJ's ROA (%) is ranked higher than
83% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. JNJ: 11.20 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.2
8.93
17.08
ROC (Joel Greenblatt) (%) 92.07
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. JNJ: 92.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 92.07
65.66
114.87
Revenue Growth (3Y)(%) 1.40
JNJ's Revenue Growth (3Y)(%) is ranked lower than
63% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.20 Max: 13.8
Current: 1.4
1.4
13.8
EBITDA Growth (3Y)(%) 9.30
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 11.20 Max: 17.3
Current: 9.3
-6.6
17.3
EPS Growth (3Y)(%) 12.40
JNJ's EPS Growth (3Y)(%) is ranked higher than
60% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 12.20 Max: 18.2
Current: 12.4
-8.6
18.2
» JNJ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

JNJ Guru Trades in Q3 2015

Jim Simons 392,000 sh (New)
Chuck Royce 9,000 sh (New)
Charles Brandes 118,509 sh (New)
Louis Moore Bacon 63,428 sh (New)
John Burbank 32,624 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
Mario Gabelli 317,847 sh (+0.86%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
Robert Olstein 71,000 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
Warren Buffett 327,100 sh (unchged)
John Hussman 1,325 sh (unchged)
Prem Watsa 82,850 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Snow 3,270 sh (unchged)
Richard Perry 292,729 sh (unchged)
Michael Price 25,000 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 10,543,562 sh (-0.31%)
Richard Snow 3,260 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

David Rolfe 5,250 sh (New)
Diamond Hill Capital 1,969 sh (New)
Jim Chanos 29,730 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Tweedy Browne Global Value 865,835 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Richard Snow 3,260 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Michael Price 25,000 sh (unchged)
Jim Chanos 5,952 sh (unchged)
David Carlson 460,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Richard Perry 292,729 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
Q2 2016

JNJ Guru Trades in Q2 2016

Yacktman Fund 3,600,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, OTCPK:NVSEF, NYSE:MRK, NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Ratios

vs
industry
vs
history
P/E(ttm) 23.52
JNJ's P/E(ttm) is ranked higher than
59% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. JNJ: 23.52 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 23.52
10.5
24
Forward P/E 19.05
JNJ's Forward P/E is ranked lower than
60% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. JNJ: 19.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.52
JNJ's PE(NRI) is ranked higher than
60% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. JNJ: 23.52 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 23.52
10.5
24
Price/Owner Earnings (ttm) 21.37
JNJ's Price/Owner Earnings (ttm) is ranked higher than
71% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. JNJ: 21.37 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.19  Med: 17.56 Max: 25.26
Current: 21.37
10.19
25.26
P/B 4.75
JNJ's P/B is ranked lower than
71% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. JNJ: 4.75 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 5.26
Current: 4.75
2.68
5.26
P/S 4.99
JNJ's P/S is ranked lower than
67% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. JNJ: 4.99 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 5
Current: 4.99
2.17
5
PFCF 24.05
JNJ's PFCF is ranked lower than
54% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. JNJ: 24.05 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.53 Max: 24.67
Current: 24.05
10.28
24.67
POCF 19.34
JNJ's POCF is ranked lower than
58% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. JNJ: 19.34 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.19 Max: 19.34
Current: 19.34
8.98
19.34
EV-to-EBIT 17.69
JNJ's EV-to-EBIT is ranked higher than
58% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. JNJ: 17.69 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.90 Max: 18.2
Current: 17.69
7.8
18.2
EV-to-EBITDA 15.34
JNJ's EV-to-EBITDA is ranked higher than
56% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. JNJ: 15.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.90 Max: 15.6
Current: 15.34
6.7
15.6
PEG 3.85
JNJ's PEG is ranked lower than
70% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. JNJ: 3.85 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.19  Med: 1.71 Max: 25.96
Current: 3.85
1.19
25.96
Shiller P/E 25.87
JNJ's Shiller P/E is ranked higher than
76% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.39 vs. JNJ: 25.87 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.52  Med: 20.77 Max: 29.97
Current: 25.87
15.52
29.97
Current Ratio 2.83
JNJ's Current Ratio is ranked higher than
58% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. JNJ: 2.83 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.05 Max: 2.83
Current: 2.83
1.2
2.83
Quick Ratio 2.47
JNJ's Quick Ratio is ranked higher than
62% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. JNJ: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.71 Max: 2.47
Current: 2.47
0.94
2.47
Days Inventory 138.17
JNJ's Days Inventory is ranked lower than
63% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. JNJ: 138.17 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.17
100.19
137.6
Days Sales Outstanding 58.74
JNJ's Days Sales Outstanding is ranked higher than
63% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. JNJ: 58.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 58.74
53.94
61.4
Days Payable 100.98
JNJ's Days Payable is ranked higher than
69% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.26 vs. JNJ: 100.98 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 100.98
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.43
JNJ's Dividend Yield is ranked higher than
73% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. JNJ: 2.43 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.89  Med: 2.84 Max: 3.84
Current: 2.43
1.89
3.84
Dividend Payout 0.55
JNJ's Dividend Payout is ranked lower than
70% of the 379 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. JNJ: 0.55 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.42 Max: 6.33
Current: 0.55
0.29
6.33
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
51% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13.00 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.56
JNJ's Forward Dividend Yield is ranked higher than
72% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. JNJ: 2.56 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.41
JNJ's Yield on cost (5-Year) is ranked higher than
73% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. JNJ: 3.41 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.65  Med: 3.98 Max: 5.39
Current: 3.41
2.65
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.10 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.83
JNJ's Price/Tangible Book is ranked lower than
90% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.59 vs. JNJ: 13.83 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.41 Max: 18.92
Current: 13.83
6.24
18.92
Price/Projected FCF 1.84
JNJ's Price/Projected FCF is ranked higher than
62% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. JNJ: 1.84 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.40 Max: 3.6
Current: 1.84
0.87
3.6
Price/DCF (Earnings Based) 2.20
JNJ's Price/DCF (Earnings Based) is ranked lower than
76% of the 80 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.31 vs. JNJ: 2.20 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.55
JNJ's Price/Median PS Value is ranked lower than
70% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. JNJ: 1.55 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.14 Max: 1.88
Current: 1.55
0.74
1.88
Price/Peter Lynch Fair Value 2.85
JNJ's Price/Peter Lynch Fair Value is ranked lower than
75% of the 173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. JNJ: 2.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.22  Med: 1.88 Max: 4.03
Current: 2.85
1.22
4.03
Price/Graham Number 3.74
JNJ's Price/Graham Number is ranked lower than
74% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. JNJ: 3.74 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.15 Max: 5.97
Current: 3.74
1.97
5.97
Earnings Yield (Greenblatt) (%) 5.71
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. JNJ: 5.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.70 Max: 12.9
Current: 5.71
5.5
12.9
Forward Rate of Return (Yacktman) (%) 11.72
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. JNJ: 11.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.00 Max: 18.4
Current: 11.72
1.8
18.4

More Statistics

Revenue (TTM) (Mil) $70,877
EPS (TTM) $ 5.32
Beta0.80
Short Percentage of Float0.87%
52-Week Range $81.79 - 126.07
Shares Outstanding (Mil)2,750.64

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 71,997 75,307 77,896
EPS ($) 6.58 7.05 7.39
EPS w/o NRI ($) 6.58 7.05 7.39
EPS Growth Rate
(3Y to 5Y Estimate)
3.38%
Dividends Per Share ($) 3.15 3.34 3.54
» More Articles for NYSE:JNJ

Headlines

Articles On GuruFocus.com
Companies Hit 52-Week Highs Jul 26 2016 
UnitedHealth Reports 28% Sales Growth in 2nd Quarter Jul 23 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
T. Rowe Price Equity Income Fund Sells Apache, Johnson & Johnson in 2nd Quarter Jul 21 2016 
What Will Happen to the Stock Market When Interest Rates Rise? Part 1 Jul 21 2016 
Microsoft in Focus as Stock Valuation Gains Ease Slightly Jul 19 2016 
Yacktman Focused Fund, Focuses Elsewhere Jul 19 2016 
Can the Procter & Gamble’s Find Its Lost Mojo? Jul 19 2016 
Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
Avoid Getting Sucked In at the Top Jul 17 2016 

More From Other Websites
Will MNK’s Segmental Growth Result in a 3Q16 Earnings Surprise? Jul 26 2016
FDA enhances warnings on group of strong antibiotics Jul 26 2016
Top 10 Dividend Aristocrats to Buy at a Discount Now Jul 26 2016
Companies Hit 52-Week Highs Jul 26 2016
Tokai's shares tumble as it halts prostate-cancer drug trial Jul 26 2016
What to Expect from Zimmer Biomet Holdings’ 2Q16 Earnings Jul 26 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology... Jul 26 2016
What’s Johnson & Johnson’s Guidance for 2016? Jul 26 2016
5 Best Stocks to Buy for the Next 50 Years Jul 26 2016
What Key Developments Did JNJ Announce in 2Q16? Jul 26 2016
The Death Of Brand Loyalty: Cultural Shifts Mean It's Gone Forever Jul 25 2016
Is Johnson & Johnson ready for pullback? Jul 25 2016
How Did JNJ’s Medical Devices Segment Perform in 2Q16? Jul 25 2016
Analysts’ Recommendations for JNJ after 2Q16 Earnings Jul 25 2016
The Zacks Analyst Blog Highlights: Bank of America, Chevron, Exxon Mobil, Johnson & Johnson and... Jul 25 2016
How Did Johnson & Johnson’s Consumer Segment Perform in 2Q16? Jul 25 2016
How Did JNJ’s Medical Devices Business Fare in 2Q16? Jul 25 2016
UnitedHealth Reports 28% Sales Growth in 2nd Quarter Jul 24 2016
Unilever sharpens P&G rivalry by buying Dollar Shave Club Jul 20 2016
Global stocks resilient amid solid corporate earnings Jul 20 2016
Business Highlights Jul 19 2016
Netflix and Philip Morris stumble; VMware and Lockheed climb Jul 19 2016
US STOCKS-S&P pulls back from record; Dow notches 8th day of gains Jul 19 2016
Markets Right Now: US end mostly lower Jul 19 2016
US STOCKS-Wall St edges down amid mixed earnings after market's record highs Jul 19 2016
Johnson & Johnson tops 2Q forecasts despite profit drop Jul 19 2016
World stocks mostly drop, Japan enjoys Pokemon-inspired rise Jul 19 2016
U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets... Jul 14 2016
Lower-cost biotech drug gets thumbs up from FDA panel Jul 12 2016
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX®... Jul 07 2016
Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease... Jun 29 2016
Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice... Jun 22 2016
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results Jun 21 2016
The Carlyle Group Engages Former Johnson & Johnson China Chairman Jesse Wu as Senior Advisor to the... Jun 20 2016
Starbucks Appoints Hans Melotte to Lead Global Supply Chain Jun 14 2016
New Data Show On-Demand, Mealtime Insulin Delivery System Enabled More than 50 Percent of Patients... Jun 13 2016
New Data Show On-Demand, Mealtime Insulin Delivery System Enabled More than 50 Percent of Patients... Jun 13 2016
Industry weighs radical shake-up of European drug pricing Jun 09 2016
Industry weighs radical shake-up of European drug pricing Jun 09 2016
J&J, GSK rheumatoid arthritis drug meets goals of large trial Jun 07 2016
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery Jun 06 2016
Johnson & Johnson Partners with Leading Organizations to Advance Education of Young Women and Girls... Jun 06 2016
Asian shares mixed pending US jobs report, Fed decision Jun 02 2016
Business Highlights Jun 02 2016
US STOCKS-Healthcare helps Wall St to slight gains; jobs report next Jun 02 2016
Markets Right Now: S&P 500 closes at high for the year Jun 02 2016
J&J to buy hair care products maker Vogue for $3.3 billion Jun 02 2016
Johnson & Johnson buying Vogue Int'l for about $3.3B Jun 02 2016
Johnson & Johnson Announces Agreement to Acquire Vogue International Jun 02 2016
Remember these? Pinto, Tylenol and other infamous recalls May 27 2016
Johnson & Johnson to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference May 25 2016
Boomer Esiason Foundation Announces Collaboration with Johnson & Johnson for First-of-Its-Kind TRU... May 23 2016
Johnson & Johnson Showcasing its Broad Innovation and Technology Strategies in Consumer and Medical... May 18 2016
J&J to stand behind talc’s safety at upcoming trials - lawyer May 17 2016
J&J to stand behind talc’s safety at upcoming trials - lawyer May 17 2016
J&J to stand behind talc’s safety at upcoming trials - lawyer May 17 2016
Johnson & Johnson Announces Collaboration with HP Inc. Subsidiary to Create Personalized Health Care... May 17 2016
Asian shares mostly lower but little changed, Japan up May 09 2016
DePuy Synthes Companies Announces Acquisition of Biomedical Enterprises, inc., A Leader in Small... May 09 2016
Johnson & Johnson to Participate in the 2016 UBS Global Healthcare Conference May 09 2016
Panel: Painkiller training should be required for physicians May 04 2016
FDA advisers reconsider training for painkiller prescribers May 04 2016
Talc powder firm to pay $55m to victim May 03 2016
Johnson & Johnson ordered to pay $55 million in talc-powder trial May 02 2016
Johnson & Johnson ordered to pay $55 million in talc-powder trial May 02 2016
If the 16-year rally in 'consumer staple' shares is ending, sell a little Fundsmith Apr 25 2016
US STOCKS-Wall Street nears record as quarterly reports roll in Apr 19 2016
GLOBAL MARKETS-Oil gains on Kuwait strike; global shares highest since Dec Apr 19 2016
US STOCKS SNAPSHOT-Wall St inches closer to record on energy, earnings Apr 19 2016
US STOCKS-Wall St nears record terrain as quarterly reports roll in Apr 19 2016
J&J shares hit new high on strong drug sales, weaker dollar Apr 19 2016
UK cost agency backs J&J cancer drug in change of heart Mar 21 2016
J Walter Thompson CEO quits after being accused of slurs Mar 17 2016
Johnson & Johnson hit with $500 million verdict in hip implant trial Mar 17 2016
Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen... Mar 16 2016
Top ad exec freely uses racist, sexist slurs -NY lawsuit Mar 11 2016
Top ad exec freely uses racist, sexist slurs -NY lawsuit Mar 10 2016
UK cost agency rejects leukaemia drug from J&J and AbbVie Mar 01 2016
J&J To Pay $72m Over Talc-Linked Cancer Death Feb 23 2016
US STOCKS-Oil fuels 'schizophrenic' rebound on Wall Street Jan 26 2016
US STOCKS-Oil fuels 'schizophrenic' rebound on Wall Street Jan 26 2016
US STOCKS SNAPSHOT-Wall Street rebounds, helped by oil, earnings Jan 26 2016
FBI probing what J&J knew about uterine surgery device - WSJ May 27 2015
Interview - New-look GSK bets on consumer health spending May 06 2015
J&J cuts full-year forecast due to strong dollar Apr 14 2015
Johnson & Johnson buys energy drink brand in India Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)